ฐานข้อมูลอันตรกิริยาระหว่างสมุนไพรกับยาแผนปัจจุบัน

Part Used : ไม่ระบุ

Activity : CYP3A4 INHIBITION

Solvent/Active Compound : decaffeinated green tea

Type of experiment : human

Type of animal : -

Type of study : Open trial

N(Total) : 11

N(Treatment) : 11

Sex : -

Age : -

Route : Oral administration

Dose/Conc.(herb) : 4 DGT capsules/day (DGT capsule contained 211+/-25 mg of green tea catechins and <1 mg of caffeine)

Duration : 14 days

Type of interaction : Pharmacokinetics

Interaction with drug : Alprazolam

Dose/Conc.(drug) : 2 mg

Result : Negative

Remark : There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/=0.05; max. concn. in plasma, 33+/-8 vs. 34+/-13 ng/mL; time to reach max. concn. in plasma, 1.4+/-1.2 vs. 1.4+/-1.2 h; area under the plasma concn. vs. time curve, 480+/-119 vs. 510 +/- 107 h-ng-ml-1; half-life of elimination, 12.3+/-1.7 vs. 13.1+/-3.4 h).

Note : Data incomplete Subject total: healthy volunteers - Results indicate that DGT is unlikely to alter the disposition of medications primarity dependent on the CYP2D6 or CYP3A4 pathways of metabolism. Abbreviation decaffeinated green tea : DGT dextromethorphan metabolic ratios: DMRS alprazola: ALPZ

---